Despite the unprecedented tumor regression and long‐term survival benefit observed with agents against programmed cell death 1 (PD‐1) or programmed cell death 1 ligand (PD‐L1), a large portion of patients do not benefit and many responders eventually relapse (Kim, Herbst, & Chen, 2018). The gene discussed is PDCD1; the disease is neoplasm.